Available Brands
Did you find this information helpful?
Author Details
Written By
Vishishta
M.Sc Microbiology

Reviewed By
Dr. Tejashwin Adiga
MBBS
Last updated : 17 Oct 2026 | 07:47 AM (IST)

Want to know more?
Read Our Editorial Policy
Quick Summary
OCTREOTIDE
Last updated on 17 Oct 2026 | 07:47 AM (IST)
OCTREOTIDE
Molecule Overview
Octreotide is an injectable medicine that mimics a natural hormone called somatostatin, which helps regulate the release of several other hormones in the body. It belongs to a class of medicines called somatostatin analogs, used to manage acromegaly (excess growth hormone) and the symptoms of certain hormone-secreting tumours such as carcinoid tumours and VIPomas. It is a prescription-only medicine, available in both short-acting and long-acting depot forms.
Medical Classification
Therapeutic Class: Hormone-regulating medicine (somatostatin analog).
Pharmacological Class: Somatostatin receptor agonist.
Drug Family: Cyclic octapeptide somatostatin analogs.
ATC Classification: H01CB02 (Octreotide).
Conditions Treated
Approved: Acromegaly (reducing growth hormone and IGF-1 levels), symptomatic treatment of metastatic carcinoid tumours (flushing and diarrhoea), and treatment of profuse watery diarrhoea associated with VIP-secreting tumours (VIPomas).
Commonly used for: Patients with acromegaly who haven't had an adequate response to surgery or radiotherapy, and patients with symptomatic neuroendocrine tumours needing hormone-related symptom control.
Off-label use (only under medical guidance): Sometimes used for severe or refractory diarrhoea from other causes, or certain gastrointestinal bleeding situations, under specialist guidance.
Available Strengths & Dosage Forms
● Injection (short-acting, subcutaneous/intravenous): commonly available as 50 mcg/mL, 100 mcg/mL, 200 mcg/mL, and 500 mcg/mL ampoules/vials.
● Injection (long-acting depot, intramuscular): commonly available as 10 mg, 20 mg, and 30 mg single-dose vials, given once every 4 weeks.
How the Molecule Works
Octreotide mimics the natural hormone somatostatin, which normally suppresses the release of several other hormones, including growth hormone, insulin, glucagon, and various gut hormones. By activating somatostatin receptors, octreotide reduces excess growth hormone in acromegaly, and reduces the release of hormones responsible for flushing and diarrhoea in carcinoid syndrome and similar conditions.
Dosage & Administration
Standard dose (short-acting, initial): Typically starts around 50-100 mcg given subcutaneously two to three times daily, adjusted based on response, before transitioning many patients to the long-acting depot form.
Condition-wise dose (long-acting depot): 10 mg, 20 mg, or 30 mg given as a single intramuscular injection once every 4 weeks, with the dose individualised based on the condition (acromegaly vs. carcinoid syndrome) and response.
Route: Subcutaneous or intravenous injection (short-acting form), or deep intramuscular injection (long-acting depot form, administered by a healthcare professional).
Missed dose: For the depot injection, the clinic reschedules the missed dose as close to the planned interval as possible; the patient does not time it themselves.
Overdose: May cause exaggerated hormone-suppressive effects such as low blood sugar or slowed heart rate; requires medical attention.
Side Effects
Common: Injection-site pain (particularly with the higher-dose depot injections), abdominal discomfort, diarrhoea, and gallstones (cholelithiasis) with longer-term use.
Serious: Significant blood sugar changes (both high and low blood sugar can occur), heart rhythm changes (bradycardia, conduction abnormalities), and thyroid function suppression (hypothyroidism) with long-term use.
Emergency symptoms: Severe abdominal pain (possible gallstone complication), signs of very low or very high blood sugar, or a very slow or irregular heartbeat.
Recovery advice: Injection-site pain from the depot form is usually mild-to-moderate and short-lived (around an hour); periodic gallbladder ultrasound and blood sugar/thyroid monitoring help catch longer-term effects of treatment early.
Warnings & Precautions
Pregnancy: Used only if clearly needed, under medical guidance; may improve fertility in acromegalic women by lowering growth hormone/IGF-1 levels, so unintended pregnancy should be discussed with premenopausal patients.
Breastfeeding: Limited transfer into breast milk observed in animal studies; discussed with the treating doctor.
Liver disease: Not formally studied in hepatic impairment for the depot form; used with caution and monitoring.
Kidney disease: Not formally studied in renal impairment for the depot form; used with caution and monitoring.
Elderly: Used with routine monitoring; no specific age-based dose adjustment established.
Children: Safety and efficacy of the long-acting depot form have not been established in children; used under specialist guidance if needed.
Drug Interactions
● Insulin, sulfonylureas, and other diabetes medicines: octreotide can affect blood sugar in either direction, so dose adjustment of diabetes medicines may be needed.
● Cyclosporine: octreotide may reduce absorption of cyclosporine, potentially reducing its effectiveness in transplant patients.
● Beta-blockers and other heart-rate-lowering medicines: combined use may increase the risk of slow heart rate (bradycardia).
● Bromocriptine: octreotide may increase the availability of bromocriptine when used together.
Monitoring Requirements
● Growth hormone and IGF-1 levels periodically (acromegaly).
● Blood sugar levels regularly, particularly in patients with diabetes.
● Thyroid function tests (TSH, free T4) periodically.
● Gallbladder ultrasound periodically, given the increased risk of gallstones with longer-term use; ECG monitoring in patients with underlying cardiac conditions.
Alternative Molecules
Lanreotide (another somatostatin analog, different dosing schedule/device); Pasireotide (a broader-spectrum somatostatin analog, used in specific resistant acromegaly or Cushing's disease settings).
Combination Therapies
Often used as a standalone hormone-regulating therapy; sometimes combined with dopamine agonists (such as cabergoline) in certain acromegaly cases with insufficient response to a somatostatin analog alone, under specialist endocrinology guidance.
● Acromegaly Medicines
● Neuroendocrine Tumour Symptom Management
● Somatostatin Analogs
FAQs
Q1.
It's used to manage acromegaly and to control symptoms like flushing and diarrhoea caused by certain hormone-secreting tumours, such as carcinoid tumours and VIPomas.
Q2.
The short-acting form is injected multiple times a day and is often used initially or for dose-finding, while the long-acting depot form is given as a single injection once every 4 weeks for ongoing maintenance treatment.
Q3.
It reduces gallbladder contraction and bile flow over time, which can lead to gallstone formation with longer-term use; periodic gallbladder monitoring is part of routine care.
Q4.
Yes, it can cause either high or low blood sugar depending on the individual, so blood sugar monitoring is important, especially in patients with diabetes.
Q5.
As a deep intramuscular injection, administered by a healthcare professional once every 4 weeks, rather than a self-administered injection.
References
Disclaimer
The information on this page is for educational purposes only and is not a substitute for medical advice. Please consult your doctor to know if this treatment is appropriate for your condition.






